Nektar Therapeutics (NKTR) Operating Leases (2019 - 2025)
Historic Operating Leases for Nektar Therapeutics (NKTR) over the last 7 years, with Q3 2025 value amounting to $69.7 million.
- Nektar Therapeutics' Operating Leases fell 1962.47% to $69.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.7 million, marking a year-over-year decrease of 1962.47%. This contributed to the annual value of $82.7 million for FY2024, which is 1605.92% down from last year.
- According to the latest figures from Q3 2025, Nektar Therapeutics' Operating Leases is $69.7 million, which was down 1962.47% from $74.1 million recorded in Q2 2025.
- In the past 5 years, Nektar Therapeutics' Operating Leases ranged from a high of $134.6 million in Q1 2021 and a low of $69.7 million during Q3 2025
- For the 5-year period, Nektar Therapeutics' Operating Leases averaged around $104.5 million, with its median value being $105.8 million (2023).
- In the last 5 years, Nektar Therapeutics' Operating Leases tumbled by 544.0% in 2021 and then crashed by 1962.47% in 2025.
- Quarter analysis of 5 years shows Nektar Therapeutics' Operating Leases stood at $125.7 million in 2021, then dropped by 10.27% to $112.8 million in 2022, then fell by 12.68% to $98.5 million in 2023, then dropped by 16.06% to $82.7 million in 2024, then dropped by 15.68% to $69.7 million in 2025.
- Its Operating Leases stands at $69.7 million for Q3 2025, versus $74.1 million for Q2 2025 and $78.5 million for Q1 2025.